Physician profile
Brandon J Mackey
NPI 1477081149
$4,919.03
in general payments reported to CMS, 2019-2025
27 companies · $456 in 2025
The $456 reported for 2025 was less than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $535 · 2021: $566 · 2022: $911 · 2023: $818 · 2024: $785 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.87 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.63 | 2019-2025 | |
| Janssen Biotech, INC. | $1,230.99 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $251.84 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $207.80 | 2021-2025 | Ilumya |
| Genzyme Corporation | $187.31 | 2021-2025 | |
| Dermavant Sciences, INC. | $171.39 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157.00 | 2019-2020 | |
| Ucb, INC. | $97.87 | 2019-2024 | Bimzelx |
| Lilly USA, LLC | $86.29 | 2019-2024 | Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.61 | 2022-2024 | Cyltezo, Spevigo |
| Almirall LLC | $82.01 | 2022-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $80.58 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $78.63 | 2023-2025 | Xolair, Erivedge |
| Organon LLC | $58.10 | 2023-2025 | Vtama, Hadlima |
| Regeneron Healthcare Solutions, INC. | $48.44 | 2021-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $38.47 | 2019-2022 | |
| Leo Pharma INC. | $38.06 | 2021-2022 | |
| Dermira, INC. | $33.51 | 2019-2020 | |
| Incyte Corporation | $33.42 | 2021-2025 | Opzelura |
| Merck Sharp & Dohme LLC | $31.67 | 2019-2022 | |
| Abiomed | $26.76 | 2024 | Impella |
| Kyowa Kirin, INC. | $23.28 | 2025 | |
| Amgen INC. | $22.41 | 2020 | |
| Organogenesis INC. | $22.14 | 2025 | Puraply Wound Matrix |
| Hill Dermaceuticals, INC. | $19.06 | 2025 | Tolak |
| Mylan Institutional INC. | $14.69 | 2023 | Hulio |
| Fidia Pharma USA INC. | $14.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.